This article is more than 5 years old. Information may no longer be current.

enVista toric MX60T IOL gets premarket approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has issued premarket approval to Bausch + Lomb for its enVista toric MX60T hydrophobic acrylic IOL for astigmatism correction, according to a press release.

Featuring a one-piece aberration-free aspheric optic with a fenestrated, step-vaulted modified C-loop haptic design, the lens demonstrated 5° or less of absolute rotation in 100% of subjects in a prospective study, the release said.

“Building on the proven features and benefits of the enVista family of IOLs, MX60T represents another innovation in the continued expansion of this lens platform,” Chuck Hess, vice president and general manager of U.S. Surgical at Bausch + Lomb, said in the release. “The addition of this new lens to our portfolio offers surgeons a wide range of IOLs with seven cylinder powers to meet their astigmatic patients’ needs.”